Notably, the dual CAR-T cells transduced with both CD19 scFv-CD28-CD3z and PSMA scFv-PD-1-intracellular trail could be inactivated by PSMA, suggesting that this concept might be feasible for optimizing the on-target, off-tumor effect of CAR. This evidence concerns the gene CD19 and neoplasm.